BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34632486)

  • 21. Prognostic Significance of Ground-Glass Opacity Components in 5-Year Survivors With Resected Lung Adenocarcinoma.
    Shigefuku S; Shimada Y; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Ikeda N
    Ann Surg Oncol; 2021 Jan; 28(1):148-156. PubMed ID: 32920721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subsolid Lesions Exceeding 3 Centimeters: The Ground-Glass Opacity Component Still Matters.
    Fan F; Zhang Y; Fu F; Gao Z; Zhao Y; Han H; Lai J; Wen Z; Ma X; Deng C; Ma Z; Wang S; Deng L; Li Y; Ye T; Chen H
    Ann Thorac Surg; 2022 Mar; 113(3):984-992. PubMed ID: 33839135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological features and prognostic implications of ground-glass opacity components on computed tomography for clinical stage I lung adenocarcinoma.
    Katsumata S; Aokage K; Ishii G; Hoshino H; Suzuki J; Miyoshi T; Tane K; Samejima J; Tsuboi M
    Surg Today; 2021 Jul; 51(7):1188-1202. PubMed ID: 33745094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solid component ratio influences prognosis of GGO-featured IA stage invasive lung adenocarcinoma.
    Sun F; Huang Y; Yang X; Zhan C; Xi J; Lin Z; Shi Y; Jiang W; Wang Q
    Cancer Imaging; 2020 Dec; 20(1):87. PubMed ID: 33308323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Zhang C; He Z; Cheng J; Cao J; Hu J
    Clin Lung Cancer; 2021 Mar; 22(2):e160-e168. PubMed ID: 33160898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer.
    Hattori A; Suzuki K; Takamochi K; Wakabayashi M; Aokage K; Saji H; Watanabe SI;
    J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1469-1480. PubMed ID: 32451073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic implications of CT-defined ground glass opacity in clinical stage I-IIA grade 3 invasive non-mucinous pulmonary adenocarcinoma.
    Ding L; Zhao J; Yang Y; Bhuva MS; Dipendra P; Sun X
    Clin Radiol; 2024 Mar; 79(3):e353-e360. PubMed ID: 38123396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ground glass opacity resection extent assessment trial
    Li H; Wang Y; Chen Y; Zhong C; Fang W
    Front Oncol; 2023; 13():1052796. PubMed ID: 36741022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer.
    Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
    Ann Thorac Surg; 2017 Jul; 104(1):313-320. PubMed ID: 28433219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors.
    Mimae T; Tsutani Y; Miyata Y; Imai K; Ito H; Nakayama H; Ikeda N; Okada M
    Ann Thorac Surg; 2020 May; 109(5):1530-1536. PubMed ID: 31981497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features and prognosis of clinical N0 non-small cell lung cancer exceeding 30 mm.
    Kagimoto A; Tsutani Y; Handa Y; Mimae T; Miyata Y; Okada M
    Jpn J Clin Oncol; 2020 Oct; 50(11):1306-1312. PubMed ID: 32901276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for lymph node metastasis and surgical methods in patients with early-stage peripheral lung adenocarcinoma presenting as ground glass opacity.
    Wang Y; Jing L; Wang G
    J Cardiothorac Surg; 2020 Aug; 15(1):121. PubMed ID: 32782020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do ground-glass opacity-dominant features have prognostic significance in node-negative adenocarcinomas with invasive components of similar sizes?
    Han SJ; Jeon JH; Jung W; Seong YW; Cho S; Kim K; Jheon S
    Eur J Cardiothorac Surg; 2020 Jun; 57(6):1189-1194. PubMed ID: 32047887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of nomogram based on whole tumour size, tumour disappearance ratio on CT and SUVmax on PET in lung adenocarcinoma.
    Song SH; Ahn JH; Lee HY; Lee G; Choi JY; Kang J; Kim EY; Han J; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Shim YM
    Eur Radiol; 2016 Jun; 26(6):1538-46. PubMed ID: 26455720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
    Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
    Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the radiological definition of part-solid tumour in lung cancer?†.
    Matsunaga T; Suzuki K; Takamochi K; Oh S
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):242-247. PubMed ID: 28119328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Nodule Density in Women With Sublobar Resection for Stage IA Adenocarcinoma.
    Phillips WW; Gill RR; Mazzola E; Armitage JR; de Forcrand C; Colson YL; Gibney BC
    Ann Thorac Surg; 2021 Oct; 112(4):1067-1075. PubMed ID: 33181131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma.
    Uehara H; Tsutani Y; Okumura S; Nakayama H; Adachi S; Yoshimura M; Miyata Y; Okada M
    Ann Thorac Surg; 2013 Dec; 96(6):1958-65. PubMed ID: 24021765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The presence of micropapillary and/or solid subtypes is an independent prognostic factor for patients undergoing curative resection for stage I lung adenocarcinoma with ground-glass opacity.
    Li R; Li Z; Yang Z; Qiu B; Tan F; Xue Q; Gao S; He J
    Transl Lung Cancer Res; 2024 Feb; 13(2):256-268. PubMed ID: 38496684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.